AFFiRiS logo_white with blue globe.PNG
AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
July 27, 2021 08:00 ET | AFFiRiS AG
AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further...
AFFiRiS logo_white with blue globe.PNG
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
May 27, 2021 05:00 ET | AFFiRiS AG
Repeated immunization with AFFITOPE® peptide active immunotherapy candidates AT04A and AT06A is safe, well-tolerated and induces a strong and long-lasting PCSK9-specific immune responseAT04A treatment...
AFFiRiS logo_white with blue globe.PNG
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
April 27, 2021 03:00 ET | AFFiRiS AG
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathologyHuman mtHTT transgenic mice treated with mAB C6-17 showed...